Zealand Pharma major shareholder announcement: Polar Capital

Published

Company announcement – No. 16 / 2024

Zealand Pharma major shareholder announcement: Polar Capital

Copenhagen, Denmark, 19 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 18 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

As of 15 March 2024, Polar Capital holds nominally 3,123,349 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 4.98% of the total share capital and total voting rights in Zealand Pharma A/S.

Please see further details in the attached notification form.

# # #

About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a presence in the U.S. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Contact:

 
Anna Krassowska, PhDVice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: ank@zealandpharma.com

Attachment

In This Story